Filtered By:
Infectious Disease: Hepatitis

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 297 results found since Jan 2013.

5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells.
In conclusion, our findings suggest that 3p-siRNA could act as a powerful bifunctional antiviral molecule with potential for developing a promising therapeutic against chronic HBV infection. PMID: 24099962 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - October 4, 2013 Category: Drugs & Pharmacology Authors: Chen X, Qian Y, Yan F, Tu J, Yang X, Xing Y, Chen Z Tags: Eur J Pharmacol Source Type: research

Hydroxyapatite nanoparticles modified by branched polyethylenimine are effective non-viral vectors for siRNA transfection of hepatoma cells in vitro.
Abstract Small interfering RNA (siRNA) technology is a powerful tool in biomedical research and holds great potential for RNA interference-based therapies for HIV, hepatitis and cancer. However, the absence of a safe and efficient method for the delivery of siRNA has become a bottleneck for their development. Nanocrystallized hydroxyapatite (nHAP) appears to be an optimal candidate non-viral gene vector for several reasons, including its good biocompatibility and ease of production, however, nHAP microemulsions cannot remain monodispersed for long periods of time. Due to their high surface energy, nHAP particles g...
Source: International Journal of Oncology - March 5, 2015 Category: Cancer & Oncology Authors: Xu XL, Yang HY, Ou B, Lin SD, Wu H, He W, Jiang QC, Luo BM, Li GP Tags: Int J Oncol Source Type: research

Targeted Delivery of siRNA against Hepatitis B Virus by PreS1 Peptide Molecular Ligand
ConclusionThe results indicated that PreS1‐9Arg may be a potential novel vector to deliver siRNA targeting liver cells.
Source: Hepatology Research - June 28, 2013 Category: Internal Medicine Authors: Wenjuan Huang, Xia Li, Min Yi, Sufen Zhu, Weixian Chen Tags: Original Article Source Type: research

Hepatic Stellate Cells in Liver Fibrosis and siRNA-Based Therapy.
Abstract Hepatic fibrosis is a reversible wound-healing response to either acute or chronic liver injury caused by hepatitis B or C, alcohol, and toxic agents. Hepatic fibrosis is characterized by excessive accumulation and reduced degradation of extracellular matrix (ECM). Excessive accumulation of ECM alters the hepatic architecture leading to liver fibrosis and cirrhosis. Cirrhosis results in failure of common functions of the liver. Hepatic stellate cells (HSC) play a major role in the development of liver fibrosis as HSC are the main source of the excessive production of ECM in an injured liver. RNA interfere...
Source: Pharmacological Reviews - August 17, 2016 Category: Drugs & Pharmacology Authors: Omar R, Yang J, Liu H, Davies NM, Gong Y Tags: Rev Physiol Biochem Pharmacol Source Type: research

Controlling HCV infection by targeting its translation initiation site in PBMCs using siRNA; In Vitro.
Abstract Hepatitis C virus infection and its complications are among the leading public health challenges, the emergence of drug-resistant variants is expected to be a major problem. A combinatorial small interfering RNA (siRNA) could be a novel triple therapy that could be suitable for genotype 4. HCV believed to be hepatotropic, but there is liable evidence about its replication in peripheral blood mononuclear cells (PBMC) of chronic HCV infected patients. These cells act as an extra-hepatic reservoir for viral recurrence and persistence, patients with HCV-RNA in PBMC showed a significantly lower response to the...
Source: Infectious Disorders Drug Targets - November 14, 2018 Category: Infectious Diseases Authors: Youssef SS, Elemeery MN, Eldein SS, Ghareeb DA Tags: Infect Disord Drug Targets Source Type: research

Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes
Conclusions: These findings show that, in the field of nucleic acid medicine, ZHER2-BNC/LP can be a useful carrier for siRNA delivery, and could also become a useful tool for gene silencing and to accomplish protein knock-down.
Source: Journal of Nanobiotechnology - June 24, 2013 Category: Nanotechnology Authors: Yuya NishimuraHiroaki MiedaJun IshiiChiaki OginoToshinobu FujiwaraAkihiko Kondo Source Type: research

Inhibition of hepatitis C virus genotype 4 replication using siRNA targeted to the viral core region and the CD81 cellular receptor.
Abstract Hepatitis C virus (HCV) is one of the most important causative agents of hepatitis worldwide. The current study aimed to evaluate the silencing effect of the small interference RNA (siRNA) molecules designed against the core region of HCV genotype 4 (HCV-4) and the CD81 gene, which is the cellular receptor for HCV in the human hepatocytes. RT-PCR was used to measure the changes in both the viral HCV core and the cellular CD81 genes induced by the specific siRNA molecules. Additionally, the fluctuations in either the viral or the cellular proteins of the target regions were tested by flow cytometry and imm...
Source: Cell Stress and Chaperones - February 13, 2020 Category: Cytology Authors: Aljowaie RM, Almajhdi FN, Ali HH, El-Wetidy MS, Shier MK Tags: Cell Stress Chaperones Source Type: research

Silencing of the scavenger receptor (Class B - Type 1) gene using siRNA-loaded chitosan nanaoparticles in a HepG2 cell model.
In this study, we investigated the use of chitosan nanoparticles as non-viral delivery carriers of siRNA. As a model target, we selected the scavenger receptor (SR-B1), due to its proposed involvement in hepatitis C virus (HCV) internalization. Low molecular weight (LMW) chitosan nanoparticles were prepared by simple ionic gelation using sodium tripolyphosphate (TPP) as a cross-linking agent; a fixed chitosan and TPP concentration of 0.1% was used, and a chitosan to TPP weight ratios of 3:1, 5:1, and 9:1 were investigated. Nanoparticle uptake efficiency was measured using FITC-labeled chitosan nanoparticles and silencing o...
Source: Colloids and Surfaces - November 3, 2014 Category: Biotechnology Authors: Farid MM, Hathout RM, Fawzy M, Abou-Aisha K Tags: Colloids Surf B Biointerfaces Source Type: research

Inhibition of hepatitis C virus using siRNA targeted to the virus and Hsp90.
Abstract Hepatitis C (HCV) is a viral disease affecting millions of people worldwide, and persistent HCV infection can lead to progressive liver disease with the development of liver cirrhosis and hepatocellular carcinoma. During treatment for hepatitis C, the occurrence of viral resistance is common. To reduce the occurrence of resistance, new viral treatments should target both viral and cellular factors. Many interactions occur between viral and host proteins during the HCV replication cycle and might be used for the development of new therapies against hepatitis C. Heat shock protein 90 (Hsp90) plays a role in...
Source: Cell Stress and Chaperones - November 16, 2016 Category: Cytology Authors: Braga AC, Carneiro BM, Batista MN, Akinaga MM, Rahal P Tags: Cell Stress Chaperones Source Type: research

Silencing of the Scavenger Receptor (Class B - Type 1) Gene Using siRNA-Loaded Chitosan Nanaoparticles in a HepG2 Cell Model
In this study, we investigated the use of chitosan nanoparticles as non-viral delivery carriers of siRNA. As a model target, we selected the scavenger receptor (SR-B1), due to its proposed involvement in hepatitis C virus (HCV) internalization. Low molecular weight (LMW) chitosan nanoparticles were prepared by simple ionic gelation using sodium tripolyphosphate (TPP) as a cross-linking agent; a fixed chitosan and TPP concentration of 0.1% was used, and a chitosan to TPP weight ratios of 3:1, 5:1, and 9:1 were investigated. Nanoparticle uptake efficiency was measured using FITC-labeled chitosan nanoparticles and silencing o...
Source: Colloids and Surfaces B: Biointerfaces - November 8, 2014 Category: Biochemistry Source Type: research

Silencing of the scavenger receptor (Class B – Type 1) gene using siRNA-loaded chitosan nanaoparticles in a HepG2 cell model
In this study, we investigated the use of chitosan nanoparticles as non-viral delivery carriers of siRNA. As a model target, we selected the scavenger receptor (SR-B1), due to its proposed involvement in hepatitis C virus (HCV) internalization. Low molecular weight (LMW) chitosan nanoparticles were prepared by simple ionic gelation using sodium tripolyphosphate (TPP) as a cross-linking agent; a fixed chitosan and TPP concentration of 0.1% was used, and a chitosan to TPP weight ratios of 3:1, 5:1, and 9:1 were investigated. Nanoparticle uptake efficiency was measured using FITC-labeled chitosan nanoparticles and silencing o...
Source: Colloids and Surfaces B: Biointerfaces - November 17, 2014 Category: Biochemistry Source Type: research

Inhibition of hepatitis C virus in mouse models by lipidoid nanoparticle-mediated systemic delivery of siRNA against PRK2
Publication date: Available online 22 March 2016 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Jae-Su Moon, Seung-Hoon Lee, Song-Hee Han, Eun-Jung Kim, Hee Cho, Wooseong Lee, Mi-Kyung Kim, Tae-Eun Kim, Hyun-Ji Park, Jin-Kyu Rhee, Seong-Jun Kim, Seung-Woo Cho, Seung Hyun Han, Jong-Won Oh Host-targeting antivirals have an advantage over direct-acting antivirals in that they have a high genetic barrier to resistance. Here, we describe in vivo anti-hepatitis C virus (HCV) efficacy of a potent siRNA targeting the protein kinase C-related kinase 2 (PRK2), which phosphorylates HCV NS5B RNA-d...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - March 21, 2016 Category: Nanotechnology Source Type: research

siRNA nanotherapeutics: a promising strategy for anti-HBV therapy
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) and liver cirrhosis worldwide. In spite of the numerous advances in the treatment of CHB, drugs and vaccines have failed because of many factors like complexity, resistance, toxicity, and heavy cost. New RNA interference (RNAi)-based technologies have developed innovative strategies to target Achilles' heel of the several hazardous diseases involving cancer, some genetic disease, autoimmune illnesses, and viral disorders particularly hepatitis B virus (HBV) infections. Naked siRNA delivery has serious challenges including failure to cross ...
Source: IET Nanobiotechnology - June 21, 2019 Category: Nanotechnology Source Type: research

PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication
A viable therapy is needed to overcome the deadlock of the incurable chronic hepatitis B (CHB). The prolonged existence of covalently closed circular DNA (cccDNA) and integrated HBV DNA in the nucleus of hepatocytes is the root cause of CHB. As a result, it is critical to successfully suppress HBV DNA replication and eliminate cccDNA. RNA interference has been proven in recent research to silence the expression of target genes and thereby decrease HBV replication. However, siRNA is susceptible to be degraded by RNA enzymes in vivo, making it difficult to deliver successfully and lacking of tissue targeting. To exploit the ...
Source: Frontiers in Immunology - April 29, 2022 Category: Allergy & Immunology Source Type: research

Targeting Human Telomerase Reverse Transcriptase by a Simple siRNA Expression Cassette in HepG2 Cells
Conclusions: Our developed simple SEC was a powerful strategy for screening highly effective RNAi-targeted sequences and showed promise for gene therapy of HCC.
Source: Hepatitis Monthly - March 30, 2015 Category: Infectious Diseases Source Type: research